Venom Week VII will be held in 2020 at the University of Florida, Gainesville, Florida, and organized by Drs. Alfred Alequas and Michael Schaer.
Background: Snakebite envenoming is a major, yet seriously neglected public health issue that disproportionaly affects the most impoverished and geopolitically disadvantaged rural communities of tropical and subtropical countries with low gross domestic product and low health care expenditure. This occupational and environmental "disease of poverty" affects at least 1.8e2.7 million people worldwide each year, causing 85e138,000 deaths, maiming 400,000 victims, and leaving an indeterminate number of survivors with chronic psychological sequelae and other post-traumatic stress disorders. Despite representing a medical emergency, and perhaps because it is not a transmissible condition, snakebite envenoming ranks low on international public health agendas. The timely parenteral administration of an effective antivenom constitutes the only currently scientifically-validated therapy for snakebite envenomings. However, widespread shortages of antivenom in many affected regions opened doors to the infiltration in the market of poorly manufactured and ineffective products that degrade user confidence and undermine legitimate antivenom producers, leading to an incongruous decline in demand for these crucial antidotes. Methods: The quantitative molecular analysis of an antivenom's ability to recognize and neutralize the toxins present in medically relevant snake venoms represents the cornerstone on which its preclinical qualification should be based. The application of proteomic technologies and other omics disciplines have contributed to a qualitative and quantitative advance in the road map towards this goal. In particular, the combination of antivenomics and in vivo neutralization assays for providing globally applicable standard metrics of the preclinical efficacy of antivenoms against homologous and heterologous venoms at molecular level. Immunoaffinity chromatographybased second-generation antivenomics (2GA) is a translational venomics approach that provides qualitative and quantitative information on the set of homologous and heterologous venom proteins presenting antivenomrecognized epitopes and those exhibiting impaired immunoreactivity. The combination of 2GA and in vivo neutralization tests constitutes a powerful toolbox for evaluating an antivenom's preclinical efficacy. Discussion: The recently developed third-generation (3G) antivenomics platform expands the analytical capability of 2GA allowing the determination of the maximal binding capacity of an antivenom towards each of the different toxins present in a venom, and to quantify the fraction of venom-specific antibodies present in a given antivenom. Protocol and applications of the 3GA platform in the preclinical evaluation of antivenoms will be illustrated with recent examples. Background: The most recent common ancestor for the rattlesnakes has been estimated at 12.7 Mya (mid-Miocene) with a center of origin in the north-central Mexican Plateau. Biogeographical data suggest dispersals northward into North America (late Miocene, 6e8 Mya), southward into Central America dating back to the late Miocene/early Pliocene (6.4À6.7 Mya), and a relatively recent (1.8À1.1 Mya) South American dispersal during the middle Pleistocene (1.1À1.0 Mya). Crotalus venoms are classified, according to their predominant expression of hemorrhagic PIII-SVMPs or heterodimeric neurotoxic PLA 2 , as type I or type II. This venom dichotomy is a shared trend throughout the Americas. However, the evolutionary routes followed by North, Central, and South American venoms are punctuated by their own characteristics. In North America, type-I and type II venoms are scatterly distributed across phylogeny. Type-I and type-II venom phenotypes in North American rattlesnakes appear to be due with recent lineageindependent losses of the genes coding for the the neurotoxic PLA 2 complex subunits. In Arizona, C. s. scutulatus type-I/type-II venom dichotomy correlates with the transition from a haemorrhagic to a neurotoxic phenotype along a South Central to South Eastern axis. The predominance in adult South American rattlesnakes (Crotalus durissus sp.) of type II venoms exhibiting increasing incapacitation and lethal activities to rodents represents an adaptive paedomorphic trait driven by the gain of neurotoxicity along the South America's North-South axis. On the other hand, in the Central American rattlesnake, C. s. simus, the two venom phenotypes are linked by an ontogenetic transition from type II to type I venom, and this compositional shift appears to be post-transcriptionally modulated by agedependent changes in the concentration of miRNAs. Methods: Multi-omic analyses of the transcriptional and translational venom gland activities also support a role for miRNAs in the ontogenetic venom compositional changes in congeneric Mexican rattlesnakes, C. simus and C. tzbacan. The finding of dual-action miRNAs, which silence the translation of neurotoxic heterodimeric PLA2 crotoxin while simultaneously up-regulating SVMP mRNAs, potentially explains the existence of the mutually exclusive type-II and type-I venom dichotomy among rattlesnakes. Discussion/Conclusion: The hypothesis that alterations of the distribution of miRNAs in response to an external cue may contribute to the mechanism generating adaptive venom variability deserves further detailed studies. Background: The use of aptamers rather than antibody-based antitoxins can result in the development of a new venom antidote, usable under severe conditions and suitable for immediate administration without risk of serious side effects. Envenomation by the family Viperidae is characterized by hemorrhage, local necrosis, edema, and systemic effects such as coagulopathy, neurotoxicity, and cardiotoxicity. Snake venom metalloproteinases (SVMPs) and disintegrins are responsible for hemorrhage and interfere with the hemostasis pathway. Metalloproteinases from snake venoms are classified into three major classes based on their structural domains; disintegrin domain is a part of the P-II and P-III SVMPs. One aim of this project is to determine the neutralization ability of anti-disintegrin polyclonal antibodies on disintegrins and P-II and P-III SVMPs. Neutralization of these molecules by the antibodies will allow the design of an Xaptamer against a disintegrin from Crotalus atrox venom and determine its neutralizing abilities on both disintegrins and SVMPs. Methods: Reversed-phase C18 HPLC was used to purify disintegrins from C. atrox venom. Disintegrins will be further biotinylated in vitro for the Xaptamer selection. The wound healing assay was conducted to test for neutralization abilities. Discussion/Conclusion: Two fractions were verified as disintegrins through N-terminal sequencing. Disintegrins did not inhibit platelet function using the sonoclot analyzer, but showed inhibition activity in the wound healing assay. Polyclonal antibodies against disintegrins were able to neutralize the disintegrins as per wound healing assay. Disintegrins will be further biotinylated in vitro for the X-aptamer selection. 
